Seeing Is Believing
Currently out of the existing stock ratings of Charles Duncan, 417 are a BUY (90.26%), 41 are a HOLD (8.87%), 4 are a SELL (0.87%).
Analyst Charles Duncan, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 49.59% that have a potential upside of 47.87% achieved within 312 days. Previously, Charles Duncan worked at PIPER SANDLER.
Charles Duncan’s has documented 899 price targets and ratings displayed on 64 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on CMPS, Compass Pathways Plc at 27-Mar-2025.
Analyst best performing recommendations are on INO (INOVIO PHARMACEUTICALS).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS) at 3/3/2020. The price target of $144 was fulfilled within 3 days with a profit of $54.6 (61.07%) receiving and performance score of 203.58.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$33
$12.94 (64.51%)
$34
17 days ago
(29-Sep-2025)
8/13 (61.54%)
$11.68 (54.78%)
113
Buy
$28
$7.94 (39.58%)
$30
22 days ago
(24-Sep-2025)
0/10 (0%)
$6.74 (31.70%)
Buy
$39
$18.94 (94.42%)
$35
1 months 5 days ago
(11-Sep-2025)
7/12 (58.33%)
$14.8 (61.16%)
671
Buy
$39
$18.94 (94.42%)
$32
1 months 7 days ago
(09-Sep-2025)
1/5 (20%)
$14.16 (57.00%)
349
Hold
$24
$3.94 (19.64%)
$23
2 months 9 days ago
(07-Aug-2025)
10/13 (76.92%)
$-0.4 (-1.64%)
157
What Year was the first public recommendation made by Charles Duncan?